IMPACT Therapeutics Inc
Company Profile
Business description
IMPACT Therapeutics Inc and its subsidiaries were principally involved in the research, development and commercialisation of pharmaceutical products. The company operates as a commercial-stage biotechnology company focused on advancing synthetic lethality (SL)-based precision anti-cancer therapies globally, delivering treatments to address the unmet medical needs of cancer patients. The company has commercialized its self-developed Core Product, senaparib, in China as a 1L maintenance therapy for ovarian cancer (OC). The company's revenue was derived from out-licensing revenue and the sales of pharmaceutical products, with the majority of revenue generated from the Chinese Mainland and the rest from the USA.
Contact
399 West Haiyang Road
Pudong New District
27th Floor, New Bund Times Square
Shanghai
CHNSector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
Stocks News & Analysis
stocks
Major ASX miner reduces aluminium exposure
stocks
Vegemite owner’s shares remain expensive on normalising profits.
stocks
Ask the analyst: Where does GYG stand following its US exit?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,037.00 | 11.20 | 0.12% |
| CAC 40 | 8,508.50 | 0.43 | 0.01% |
| DAX 40 | 25,765.99 | 13.32 | -0.05% |
| Dow JONES (US) | 52,900.07 | 594.83 | 1.14% |
| FTSE 100 | 10,648.67 | 30.36 | -0.28% |
| HKSE | 23,616.32 | 266.29 | 1.14% |
| NASDAQ | 25,832.67 | 207.36 | -0.80% |
| Nikkei 225 | 69,737.69 | 6.38 | -0.01% |
| NZX 50 Index | 13,763.10 | 144.68 | 1.06% |
| S&P 500 | 7,483.24 | 0.01 | 0.00% |
| S&P/ASX 200 | 8,831.00 | 12.70 | 0.14% |
| SSE Composite Index | 4,041.24 | 2.41 | -0.06% |